Josh Boron
YOU?
Author Swipe
View article: Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia Open
Relapsed or refractory acute myeloid leukemia (AML) is associated with poor outcomes and resistance to therapy. The addition of venetoclax, a BCL-2 antagonist, to lower-intensity therapies results in improved survival in the first-line set…
View article: Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia Open
Treatment paradigms for acute myeloid leukemia (AML) have evolved at a rapid pace in recent years. The combination of venetoclax with a hypomethylating agent prolonged survival in clinical trials when compared to hypomethylating agent mono…